


[Handwritten signature]
PATENT
4/6/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

[Handwritten signature: Tami Barnas]
Tami Barnas



[Handwritten date: 3/29/01]
Date

RECEIVED

Applicant: Webb, et al.

Serial No.: 09/715,891

Filed: November 17, 2000

For: MHC CLASS II ANTIGEN-PRESENTING
SYSTEMS AND METHODS FOR
ACTIVATING CD4⁺ T CELLS

Group: 1644

Examiner: Unassigned

Our Ref.: TSRI 536.1 Div 2

APR 05 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 09/194,285, to which the present application is related by division, filed on April 12, 1999, now pending. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the related patent application 09/194,285.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application/before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.


Respectfully submitted,

3/29/01
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

P:\TAMI\2001\EH\IDS\SCR2289P.IDS.FORM.REF.PREV.NO.FEE



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Tami Barnas

Tami Barnas

3/14/01

Date of Deposit

RECEIVED

APR 05 2001

TECH CENTER 1600/2900

Applicant: Webb, et al.

Serial No.: 09/194,285

Filed: April 12, 1999

For: MHC CLASS II ANTIGEN
PRESENTING SYSTEMS AND
METHODS FOR ACTIVATING
CD4⁺ T CELLS

Group Art Unit: 1644

Examiner: F.P. VanderVegt

Our Ref.: TSRI 536.1

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited

information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17 (p) in accordance with 37 CFR 1.97(c)(2).

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

3/14/01
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937